Skip to main content

Table 4 Comparison between survivors and non-survivors in COVID-19 patients with cancer

From: Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study

Clinical features

All patients (n = 103)

Survivor (n = 91)

Non-survivor (n = 12)

P-value

Age

66.0 (24.0–90.0)

66 (24.0–90.0)

66 (56.0–81.0)

0.487

Gender

   

0.061

 Female

47 (45.6%)

45 (44.6%)

2 (16.7%)

 

 Male

56 (54.4%)

56 (55.4%)

10 (83.3%)

 

Smoking

20 (19.4%)

16 (17.6%)

4 (33.3%)

0.242

Comorbidities

    

 Diabetes

14 (13.6%)

13 (14.3%)

1 (8.3%)

1.000

 Hypertension

37 (35.9%)

36 (39.6%)

1 (8.3%)

0.052

 Heart disease

11 (10.7%)

9 (9.9%)

2 (16.7%)

0.613

Symptoms

    

 Fever

73 (70.9%)

63 (69.2%)

10 (83.3%)

0.501

 Cough

70 (68.0%)

63 (69.2%)

7 (58.3%)

0.183

 Dyspnea

24 (23.3%)

16(17.6%)

8 (66.7%)

0.003

 Vomiting

5 (4.9%)

4 (4.4%)

1 (8.3%)

0.34

 Diarrhoea

7 (6.8%)

6 (6.7%)

1 (8.3%)

0.235

Laboratory findings

    

 WBC (× 109/L)

5.29 (1.90–25.10); n = 100

5.09 (1.90–25.10); n = 88

7.36 (3.50–18.80); n = 12

 < 0.001

 Neutrophil (× 109/L)

3.49 (0.67–22.40); n = 100

3.25 (0.67–22.40); n = 88

6.85 (1.50–17.36); n = 12

 < 0.001

 Lymphocyte (× 109/L)

1.06 (0.22–2.89); n = 100

1.15 (0.33–2.89); n = 88

0.64 (0.22–2.40); n = 12

0.012

 NLR

2.93 (0.64–32.23); n = 100

2.64 (0.64–24.76); n = 88

11.7 (2.88–32.32); n = 12

 < 0.001

 CRP (mg/L)

2.52 (0.14–280.32); n = 90

1.79 (0.14–177.80); n = 81

80.00 (4.80–280.32); n = 9

 < 0.001

 ALT (U/L)

19.17 (4.50–131.20); n = 97

19.17 (4.50–131.20); n = 85

16.50 (6.00–68.30); n = 12

0.634

 AST (U/L)

21.70 (10.00–147.20); n = 84

21.20 (10.00–147.20); n = 72

31.35 (12.00–92.6); n = 12

0.164

  1. WBC white blood cell, NLR leukocyte to lymphocyte ratio, CRP C-reactive protein, ALT alanine transaminase, AST Aspartate transaminase